Demulcent Eye Drops Market Size & Share 2022 to 2030

Market Size by Active Pharmaceutical Ingredient Type (Cellulose Derivatives, Dextran 70, Polyols, Polymers), by Drug formulation (Preservative Based, Non-Preservative Based), Medication Type, Distribution Channel & Forecast.

Report ID: GMI5351

Published Date: September 2022

Report Format: PDF

Download Free PDF

Demulcent Eye Drops Market Size

Demulcent Eye Drops Market size was worth more than USD 1.8 billion in 2021 and is expected to grow at a CAGR of more than 6% through 2030. Easy product accessibility and increased availability will push industry growth.

Demulcent Eye Drops Market

Growing cases of various eye disorders across the world is the primary factor propelling the market expansion. Recent data reveals that dry eye disease (DED) affects around 5% adult Americans. Notably, DED leads to numerous complications such as microaneurysm, optic nerve injury, and retinal thickness. Increase in instances of dry eye disease is one of the main factors that will boost demand for demulcent eye drops. Additionally, higher pervasiveness of ocular ailments across developing nations, especially among geriatric population will augment the demulcent eye drops market outlook.

Demulcent Eye Drops Market Trends

One of the key factors preventing the business from growing is the fact that demulcent eye drops, which are readily available over-the-counter, have a variety of negative effects. These eye drops are preserved using ingredients including purite, EDTA, and BAK to maintain pH level of tear film. Excessive or incorrect usage of such medications may cause adverse reactions such as allergies and ocular toxicity. The looming chances of discontinuation of certain ocular eye drops with preservatives may restrain the market growth.

Demulcent Eye Drops Market Analysis

Demulcent Eye Drops Market , by API Type

The demulcent eye drops market is divided into polyols, dextran 70, polymers, cellulose derivatives, and others, based on active pharmaceutical ingredient types. The polyols segment crossed USD 550 million in 2021. The cases of digital eye strain is rising as a result of the growing usage of electronic gadgets. Furthermore, a notable rise in retinal diseases and eye treatments has stimulated segment share.

Depending on drug formulation, the demulcent eye drops market is segmented into preservative based and non-preservative-based products. The non-preservative-based segment is set to surpass USD 1 billion by 2030. Preservatives such as sodium chlorite, benzalkonium chloride (BAK), etc. are used in eye drop formulations which are harmful at times.

The non-preservative-based demulcent eye drops segment is expected to develop in the forthcoming years owing to consumer preference for product due to the growing awareness of the eye-health risks caused by preservatives.

The market is categorized into over the counter (OTC) and prescriptions, as per medication type. The OTC segment exceeded USD 1 billion in 2021. Over-the-counter medications are the ones that may be purchased without a prescription, ensuring easier access to pharmaceuticals. Increased availability and accessibility of demulcent eye drops to the general public through OTC is impelling the segment demand.

Demulcent Eye Drops Market, by Distribution Channel

In terms of distribution channel, worldwide demulcent eye drops market is categorized into retail pharmacies, online pharmacies, and hospital pharmacies. The retail pharmacies segment held more than 50% business share in 2021 and is projected to record significant growth rate over the study period. The availability of affordable demulcent eye drops at retail medical stores and the rising acceptance of over-the-counter products are giving push to the industry value.

Demulcent Eye Drops Market, By Region, 2021 ( USD Million)

Europe demulcent eye drops market is anticipated to surpass USD 875 million by 2030. This is due to growing elderly population base and the significant increase in the patients suffering from dry eye disease in the European nations. The product demand will soar in the coming years, resulting from the consequences of DED such as corneal ulcers, vision loss, and decreased quality of life.

Demulcent Eye Drops Market Share

Firms like

Johnson and Johnson Services Inc.
Alcon Inc.
OASIS Medical
Allegan (AbbVie Inc.)
Prestige Consumer Healthcare Inc.
Santen Pharmaceutical Co. Ltd.
Bausch Health Companies Inc.
Aurolab
Otsuka Pharmaceutical Co.,Ltd.
Sentiss Pharma Pvt. Ltd.
Sun Pharmaceutical Industries Ltd.
URSAPHARM Arzneimittel GmbH

are the major competitors in the demulcent eye drops market.

In order to establish a strong market position, the manufacturers are strategically focusing on creating innovative solutions to meet the requirements of the customers. For instance, in January 2022, Systane Complete Preservative-Free Lubricant Eye Drops was made available in Europe by Alcon. This strategy widened Alcon's footprint in the massive and rapidly expanding artificial tears industry, generating sales worth over USD 1 billion annually.

Impact of COVID-19 Pandemic

The COVID-19 outbreak negatively affected almost every industry and organization, irrespective of size, plummeting the global economy. Due to the lack of both critical and non-essential medical supplies, there was a turmoil in the medical sector. The disruption of the supply chain impacted the production and shipping of demulcent eye drops, hampering the industry growth. However, growing sales of OTC demulcent eye drops, in tandem with shifting consumer preference for purchasing through online pharmacies will aid the global market to recover and grow in the coming years.

The demulcent eye drops market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2030, for the following segments:

By Active Pharmaceutical Ingredient Type

Cellulose Derivatives
Dextran 70
Polyols
Polymers
Others

By Drug Formulation

Preservative Based
Non-Preservative Based

By Medication Type

Over-the-counter (OTC)
Prescription

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

The above information is provided for the following regions and countries:

North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Others
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Others

Authors: Mariam Faizullabhoy, Gauri Wani

Demulcent Eye Drops Market Scope

Demulcent Eye Drops Market Size
Demulcent Eye Drops Market Trends

Demulcent Eye Drops Market Analysis
Demulcent Eye Drops Market Share

Report Content

Chapter 1 Methodology & Scope

1.1 Methodology

1.2 Base estimates and working

1.2.1 North America

1.2.2 Europe

1.2.3 Asia Pacific

1.2.4 Latin America

1.2.5 MEA

1.3 Forecast parameters

1.4 Data validation

1.5 Data sources

1.5.1 Secondary

1.5.1.1 Paid sources

1.5.1.2 Unpaid sources

1.5.2 Primary

Chapter 2 Executive Summary

2.1 Demulcent eye drops industry 360⁰ synopsis, 2017 - 2030

2.1.1 Business trends

2.1.2 Active pharmaceutical ingredient type trends

2.1.3 Drug formulation trends

2.1.4 Medication type trends

2.1.5 Distribution channel trends

2.1.6 Regional trends

Chapter 3 Demulcent Eye Drops Industry Insights

3.1 Industry segmentation

3.2 Industry landscape, 2017 - 2030

3.3 Industry impact forces

3.3.1 Growth drivers

3.3.1.1 Surge in the prevalence of eye diseases

3.3.1.2 Innovative drug formulation launches due to advancements in technology

3.3.1.3 Growing awareness regarding eye diseases among population base

3.3.2 Industry pitfalls & challenges

3.3.2.1 Side-effects associated with demulcent eye drops solutions

3.3.2.2 Numerous challenges encountered during treatment of various eye diseases

3.4 Growth potential analysis

3.4.1 By active pharmaceutical ingredient type

3.4.2 By drug formulation

3.4.3 By medication type

3.4.4 By distribution channel

3.5 COVID- 19 impact analysis

3.6 Industry ecosystem analysis

3.6.1 Raw materials and component suppliers

3.6.2 Manufacturers

3.6.3 Distribution channel analysis

3.6.4 End users

3.6.5 Vendor matrix

3.7 Epidemiological analysis

3.8 Pipeline analysis

3.9 Technology and innovation landscape, 2021

3.10 Regulatory landscape

3.10.1 U.S.

3.10.2 Europe

3.10.3 Asia Pacific

3.11 Porter's analysis

3.11.1 Bargaining power of suppliers

3.11.2 Bargaining power of buyers

3.11.3 Threat of new entrants

3.11.4 Threat of substitutes

3.11.5 Industry rivalry

3.12 Competitive landscape, 2021

3.12.1 Alcon Inc.

3.12.2 Bausch Health Companies Inc.

3.12.3 Johnson and Johnson Services, Inc.

3.12.4 Company matrix analysis, 2021

3.13 PESTEL analysis

Chapter 4 Demulcent Eye Drops Market, By Active Pharmaceutical Ingredient Type

4.1 Key segment trends

4.2 Cellulose Derivatives

4.2.1 Market size, by region, 2017 - 2030 (USD Million)

4.3 Dextran 70

4.3.1 Market size, by region, 2017 - 2030 (USD Million)

4.4 Polyols

4.4.1 Market size, by region, 2017 - 2030 (USD Million)

4.5 Polymers

4.5.1 Market size, by region, 2017 - 2030 (USD Million)

4.6 Others

4.6.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 5 Demulcent Eye Drops Market, By Drug Formulation

5.1 Key segment trends

5.2 Preservative Based

5.2.1 Market size, by region, 2017 - 2030 (USD Million)

5.3 Non-Preservative Based

5.3.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 6 Demulcent Eye Drops Market, By Medication Type

6.1 Key segment trends

6.2 Over-the-counter (OTC)

6.2.1 Market size, by region, 2017 - 2030 (USD Million)

6.3 Prescription

6.3.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 7 Demulcent Eye Drops Market, By Distribution Channel

7.1 Key segment trends

7.2 Hospital Pharmacies

7.2.1 Market size, by region, 2017 - 2030 (USD Million)

7.3 Retail Pharmacies

7.3.1 Market size, by region, 2017 - 2030 (USD Million)

7.4 Online Pharmacies

7.4.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 8 Demulcent Eye Drops Market, By Region

8.1 Key regional trends

8.2 North America

8.2.1 Market size, by country, 2017 - 2030 (USD Million)

8.2.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.2.3 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.2.4 Market size, by medication type, 2017 - 2030 (USD Million)

8.2.5 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.2.6 U.S.

8.2.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.2.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.2.6.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.2.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.2.7 Canada

8.2.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.2.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.2.7.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.2.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.3 Europe

8.3.1 Market size, by country, 2017 - 2030 (USD Million)

8.3.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.3.3 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.3.4 Market size, by medication type, 2017 - 2030 (USD Million)

8.3.5 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.3.6 Germany

8.3.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.3.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.3.6.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.3.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.3.7 UK

8.3.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.3.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.3.7.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.3.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.3.8 France

8.3.8.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.3.8.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.3.8.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.3.8.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.3.9 Spain

8.3.9.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.3.9.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.3.9.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.3.9.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.3.10 Italy

8.3.10.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.3.10.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.3.10.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.3.10.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.4 Asia Pacific

8.4.1 Market size, by country, 2017 - 2030 (USD Million)

8.4.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.4.3 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.4.4 Market size, by medication type, 2017 - 2030 (USD Million)

8.4.5 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.4.6 China

8.4.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.4.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.4.6.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.4.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.4.7 Japan

8.4.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.4.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.4.7.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.4.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.4.8 India

8.4.8.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.4.8.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.4.8.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.4.8.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.4.9 Australia

8.4.9.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.4.9.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.4.9.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.4.9.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.4.10 South Korea

8.4.10.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.4.10.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.4.10.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.4.10.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.5 Latin America

8.5.1 Market size, by country, 2017 - 2030 (USD Million)

8.5.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.5.3 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.5.4 Market size, by medication type, 2017 - 2030 (USD Million)

8.5.5 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.5.6 Brazil

8.5.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.5.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.5.6.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.5.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.5.7 Mexico

8.5.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.5.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.5.7.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.5.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.6 Middle East & Africa

8.6.1 Market size, by country, 2017 - 2030 (USD Million)

8.6.2 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.6.3 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.6.4 Market size, by medication type, 2017 - 2030 (USD Million)

8.6.5 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.6.6 Saudi Arabia

8.6.6.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.6.6.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.6.6.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.6.6.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.6.7 South Africa

8.6.7.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.6.7.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.6.7.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.6.7.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

8.6.8 UAE

8.6.8.1 Market size, by active pharmaceutical ingredient type, 2017 - 2030 (USD Million)

8.6.8.2 Market size, by drug formulation, 2017 - 2030 (USD Million)

8.6.8.3 Market size, by medication type, 2017 - 2030 (USD Million)

8.6.8.4 Market size, by distribution channel, 2017 - 2030 (USD Million)

Chapter 9 Company Profiles

9.1 Competitive dashboard, 2021

9.2 Johnson and Johnson Services, Inc.

9.2.1 Business overview

9.2.2 Financial data

9.2.3 Drug formulation landscape

9.2.4 Strategic outlook

9.2.5 SWOT analysis

9.3 Alcon Inc.

9.3.1 Business overview

9.3.2 Financial data

9.3.3 Drug formulation landscape

9.3.4 Strategic outlook

9.3.5 SWOT analysis

9.4 OASIS Medical

9.4.1 Business overview

9.4.2 Financial data

9.4.3 Drug formulation landscape

9.4.4 Strategic outlook

9.4.5 SWOT analysis

9.5 Allergan (AbbVie Inc.)

9.5.1 Business overview

9.5.2 Financial data

9.5.3 Drug formulation landscape

9.5.4 Strategic outlook

9.5.5 SWOT analysis

9.6 Prestige Consumer Healthcare Inc.

9.6.1 Business overview

9.6.2 Financial data

9.6.3 Drug formulation landscape

9.6.4 Strategic outlook

9.6.5 SWOT analysis

9.7 Santen Pharmaceutical Co., Ltd.

9.7.1 Business overview

9.7.2 Financial data

9.7.3 Drug formulation landscape

9.7.4 Strategic outlook

9.7.5 SWOT analysis

9.8 Bausch Health Companies Inc.

9.8.1 Business overview

9.8.2 Financial data

9.8.3 Drug formulation landscape

9.8.4 Strategic outlook

9.8.5 SWOT analysis

9.9 Aurolab

9.9.1 Business overview

9.9.2 Financial data

9.9.3 Drug formulation landscape

9.9.4 Strategic outlook

9.9.5 SWOT analysis

9.10 Otsuka Pharmaceutical Co.,Ltd.

9.10.1 Business overview

9.10.2 Financial data

9.10.3 Drug formulation landscape

9.10.4 Strategic outlook

9.10.5 SWOT analysis

9.11 Sentiss Pharma Pvt. Ltd.

9.11.1 Business overview

9.11.2 Financial data

9.11.3 Drug formulation landscape

9.11.4 Strategic outlook

9.11.5 SWOT analysis

9.12 Sun Pharmaceutical Industries Ltd.

9.12.1 Business overview

9.12.2 Financial data

9.12.3 Drug formulation landscape

9.12.4 Strategic outlook

9.12.5 SWOT analysis

9.13 URSAPHARM Arzneimittel GmbH

9.13.1 Business overview

9.13.2 Financial data

9.13.3 Drug formulation landscape

9.13.4 Strategic outlook

9.13.5 SWOT analysis

Authors: Mariam Faizullabhoy, Gauri Wani

For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at [email protected]

Explore Our Licensing Options:

Immediate Delivery Available

Premium Report Details

Base Year: 2021

Companies covered: 12

Tables & Figures: 238

Countries covered: 17

Pages: 240

Download Free PDF